Clinical Trial Update: Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab

View source ↗

Summary

Narsoplimab has been approved for marketing for hematopoietic stem cell transplant-associated thrombotic microangiopathy, and the document notes a single-patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Drugs mentioned

• Narsoplimab (narsoplimab)

Snippet

Sponsor: Omeros Corporation | Conditions: Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA) | Status: APPROVED_FOR_MARKETING